Molecular markers of treatment irregularity of statins: influence of polymorphisms in SLCO1B1 and SLCO1B3.

doi:10.1080/14622416.2025.2562797

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular markers of treatment irregularity of statins: influence of polymorphisms in SLCO1B1 and SLCO1B3.

Pharmacogenomics - 1 Jan 2025

Benelli Jéssica Louise, Smiderle Lisiane, de Almeida Silvana, Hutz Mara Helena, Van der Sand Cézar R, Van der Sand Luiz C, Ferreira Maria E W, Pires Renan C, Fiegenbaum Marilu

Abstract excerpt

BACKGROUND AND AIMS: The SLCO gene family encodes OATP-like transporters that interact with statins and may influence their efficacy. Consequently, these genes are key targets in pharmacogenetic studies, and associations between SLCO1B1 variants and statin therapeutic response have already been demonstrated. The aim of this study was to evaluate the association between the SLCO1B1 gene polymorphisms rs2306283,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Atorvastatin

Share to Cohort Studies

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Liver-Specific Organic Anion Transporter 1

Share to Polymorphism, Single Nucleotide

Share to Simvastatin

Share to Solute Carrier Organic Anion Transporter Family Member 1B3

Source

Open in PubMed Open full text

Identifiers

PMID: 41020786
DOI: 10.1080/14622416.2025.2562797
PMCID: PMC12582068

Genes

SLCO1B1
SLCO1B3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular markers of treatment irregularity of statins: influence of polymorphisms in SLCO1B1 and SLCO1B3.PMID 41020786Read ↗

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of StatinsSemantic proximity Read ↗

An update on efflux and uptake transporters as determinants of statin response.Semantic proximity Read ↗

Impact of SLCO1B1 and ABCB1 variants on statin efficacy and toxicity in a Tunisian population.Semantic proximity Read ↗

Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).Semantic proximity Read ↗

Predictive value of<i>SLCO1B1</i>c.521T>C polymorphism on observed changes in the treatment of 1136 statin-usersSemantic proximity Read ↗

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users.Semantic proximity Read ↗

Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis.Semantic proximity Read ↗

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variantsSemantic proximity Read ↗

SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients.Semantic proximity Read ↗

Transporter Genes and statin-induced Hepatotoxicity.Semantic proximity Read ↗

Effects of apolipoprotein E and solute carrier organic anion transporter family member 1B1 gene polymorphisms on statin efficacy and safety in dyslipidemic patients.Semantic proximity Read ↗

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.